- bluebird bio (NASDAQ:BLUE) and apceth Biopharma GmbH enter into a strategic manufacturing agreement providing for the future European commercial production of bluebird's Lenti-D product candidate for cerebral adrenoleukodystropy and its LentiGlobin product candidate for transfusion-dependent β-thalassemia.
- This agreement follows a successful multi-year manufacturing relationship and provides bluebird bio with European commercial manufacturing capabilities.
- Under the multiyear agreement, apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for both products.
- Financial terms are not disclosed.